In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonistSource: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007
Unique receptor dissociation kinetics of the novel endothelin receptor antagonist macitentan Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407Source: Eur Respir J 2007; 30: Suppl. 51, 26s Year: 2007
Rate of onset of action of aclidinium bromide, a novel, long-acting, muscarinic antagonist Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
AZD3199: A potent and selective β2 -adrenergic receptor agonist with rapid onset of action Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
GB001 is a potent, insurmountable DP2 antagonist with long receptor residence time and extended pharmacodynamic effects Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020
The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan Source: Annual Congress 2010 - Airway smooth muscle cells Year: 2010
Vasopressin is involved in endothelin receptor antagonist-induced fluid retention in rat. Differential effect of selective ETA and dual ETA/ETB receptor antagonists Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Carmoterol, a new long-acting β2 -agonist, positively interacts with M3 -muscarinic antagonist Source: Eur Respir J 2005; 26: Suppl. 49, 215s Year: 2005
The novel dual D2 dopamine receptor, β2 -adrenoceptor agonist Viozan™ (AR-C68397AA) is well tolerated in a dog model Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001
PKA/cAMP-independent transactivation of glucocorticoid receptor by long acting β2 agonists Source: Eur Respir J 2006; 28: Suppl. 50, 103s Year: 2006
Pharmacological activities of R-113281, a triple NK1 /NK2 /NK3 neurokinin receptor antagonist Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004
An orally available, highly selective 5-hydroxytryptamine 2B (5-HT2B) receptor antagonist ameliorating pulmonary and dermal fibrosis Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019
Muscarinic receptor selectivity of aclidinium bromide and glycopyrrolate in vitro Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
Ligand independent activation of the glucocorticoid receptor by long acting β2 agonists Source: Eur Respir J 2004; 24: Suppl. 48, 317s Year: 2004
The novel dual D2 dopamine receptor, β2 -adrenoceptor agonist, Viozan™ (AR-C68397AA) improves quality of life and perception of efficacy Source: Eur Respir J 2001; 18: Suppl. 33, 3s Year: 2001
Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors and beyond Source: Eur Respir J, 56 (2) 2001610; 10.1183/13993003.01610-2020 Year: 2020
An oral selective M3 cholinergic receptor antagonist in COPD Source: Eur Respir J 2006 Oct 01;28(4):772-780 Year: 2006
Evaluation of a selective 5-hydroxytryptamine 2B receptor antagonist designed to alter the fibrotic process Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017